Evidence map›Paper›PMID 38049333›Full record

ArticleZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi2023

[Efficacy and safety of fourth-generation CD19 CAR-T expressing IL7 and CCL19 along with PD-1 monoclonal antibody for relapsed or refractory large B-cell lymphoma].

T Yu, H Liu, W Lei, P P Chen, A Q Zhao, X G Yuan, J M Gao, W B Qian

Abstract readEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Article in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Advances in IL-7 Research on Tumour Therapy.Pharmaceuticals (Basel, Switzerland) · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

T YuDepartment of Hematology, the Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310009, China.
H LiuDepartment of Hematology, the Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310009, China.
W LeiDepartment of Hematology, the Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310009, China.
P P ChenDepartment of Hematology, the Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310009, China.
A Q ZhaoDepartment of Hematology, the Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310009, China.
X G YuanDepartment of Hematology, the Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310009, China.
J M GaoWenzhou Medical University Laboratory Medicine, Wenzhou 325035, China.
W B QianDepartment of Hematology, the Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310009, China.

Funding

Clinical Medical Research Project of Zhejiang Medical Association 2022ZYC-Z21National Natural Science Foundation of China 82170219
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Immunotherapy, AdoptiveLymphoma, Large B-Cell, DiffuseAntibodies, MonoclonalAntigens, CD19Chemokine CCL19HumansInterleukin-7Neurotoxicity SyndromesProgrammed Cell Death 1 ReceptorReceptors, Chimeric AntigenAntibodies, MonoclonalAntigens, CD19CCL19 protein, humancell-associated neurotoxicityChemokine CCL19Interleukin-7Programmed Cell Death 1 ReceptorReceptors, Chimeric AntigenChimeric antigen receptor T cellsImmune checkpoint inhibitorImmune related adverse reactionLarge B-cell lymphoma

Identifiers

PMID38049333
PMCPMC10694076

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.